RESEARCH Open Access



# MiR-199a/b-3p inhibits colorectal cancer cell proliferation, migration and invasion through targeting PAK4 and BCAR3

Junjie Hou<sup>1,2</sup>, Xuguang Mi<sup>2</sup>, Ning Liu<sup>3</sup>, Xiaonan Li<sup>2</sup>, Xiao-nan Li<sup>2</sup>, Ying Yang<sup>2</sup>, Xiaodan Lu<sup>2</sup>, Yanqiu Fang<sup>2</sup> and Ning-Yi Jin<sup>1,4\*</sup>

### **Abstract**

**Background:** Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. P21 activated kinase 4 (*PAK4*) and Breast cancer anti-estrogen resistance 3 (*BCAR3*) have been reported to be involved in numerous aspects in tumorous progression. In this study, we propose to screen multi-targeted microRNAs. (miRNAs), which simultaneously inhibit neoplastic evolution through suppressing the transcription of target genes.

**Methods:** MTT and Colony formation assays measured cell's viability and proliferation. Scratch wound and Transwell assays detected the ability in migration and invasion for SW116 cells. The multi-targeted microRNAs of *PAK4* and *BCAR3* were predicted using bioinformatics analysis and verified by conducting dual luciferase reporter assay, western blot and gRT-PCR that could detect the expression levels of *miR-199a/b-3p*.

**Results:** The knockdown of *PAK4* significantly impeded proliferation and colony formation of SW1116 cells when the knockdown of *BCAR3* hindered migration and invasion of SW1116 cells. MiR-199a/b-3p directly targeted the 3'-UTR of *PAK4* and *BCAR3*, further effected proliferation, colony formation, migration, and invasion of SW1116 cells. *PAK4* or *BCAR3* overexpression could partially reversed inhibitory effects of miR-199a/b-3p.

**Conclusions:** These results provided a new multi-targeted cite for cancerous suppressant to improve the prognosis of CRC inpatients.

**Keywords:** miR-199a/b-3p, Viability, Mobility, PAK4, BCAR3, Colorectal cancer (CRC)

### Introduction

Colorectal cancer (CRC) is the fourth most deadly cancer in the world, accounting for 10 percent of diagnosed cancers and cancer-related deaths worldwide [1]. Nearly 900,000 people die of CRC each year [2]. Owing to aging population and dietary habits, the risk of CRC is high in high-income countries. Some other factors such as obesity, smoking, and lack of physical activity also increase the risk of CRC [3]. Much progress has been made in the

treatment of CRC with surgical resection, adjuvant chemotherapy and radiotherapy. However, the recurrence and metastasis rate of CRC are still high [4]. Therefore, it is essential to elucidate the underlying mechanisms involving in the progression and development of this disease.

P21 activated kinase 4 (*PAK4*) is a member of Group 2 of the p21 activated kinases, which are downstream effectors of CdC42 and Rac1 and participate in biological behaviors of cancer [5]. It has been shown to suppress cell proliferation and its expression was upregulated in various cancers [6, 7]. A study on glioblastoma suggested that *PAK4* was down-regulated by miR-485 and inhibited the malignant biological behavior of glioblastoma cells [8]. In

<sup>&</sup>lt;sup>1</sup> Medical College, Yanbian University, Yanji 133002, China Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third partial in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

<sup>\*</sup>Correspondence: ningyik1@126.com

esophageal cancer, miR-199a-3p was reported to reduce cell proliferation by targeting *PAK4* [9]. Moreover, some studies have shown that certain miRNAs had suppressive effects on CRC cells through targeting *PAK4* [10, 11]. The breast cancer anti-estrogen resistance 3 (*BCAR3*) is the member of novel Src homology 2 (SH2) containing protein (NSP) family [12]. Recent study showed that overexpression of *BCAR3* regulated cytoskeletal rearrangement [13]. It was also reported that *BCAR3* overexpression increased cell migration and invasion in endometriosis [14]. However, the role of *BCAR3* in CRC remains unclear.

In recent years, miRNAs have been shown to play a significant role in cancer occurrence, metastasis, and progression [15]. They are small noncoding RNAs of about 22 nucleotides in length and are crucial post-transcriptional and epigenetic regulators of gene expression in eukaryotes [16]. Increasing research have indicated that some miRNAs are important modulators on the progression of CRC [17, 18].

In this study, we aimed to explore the role of *PAK4* and *BCAR3* in CRC. We silenced the expression of *PAK4* and *BCAR3* separately and found that these two genes had different role on CRC cells. In view of the diversity of miRNA targets, we screened out miRNAs that inhibited both genes through the bioinformatics database. Surprisingly, we identified miR-199a/b-3p as the potential target miRNA of *PAK4* and *BCAR3*. Our results suggested that miR-199a/b-3p inhibited the proliferation, colony formation of CRC cells through targeting *PAK4*. Meanwhile, the inhibitory effects on migration and invasion were regulated by targeting *BCAR3*.

### **Materials and methods**

### Cell line and cell culture

Human CRC cells (SW1116) were obtained from the Biochemistry and Cell Biology at the Chinese Academy of Sciences (Shanghai, China). SW1116 cells were cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells were cultured in humidified incubator at 37 °C with 5% CO2.

### Cell viability by MTT assay

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Sigma-Aldrich. SW1116 cells were seeded at 10,000 cells per well in 96-well plates. Cell proliferation was determined at 24, 48, and 72 h using MTT assay. MTT was dissolved in phosphate buffered saline solution at the concentration of 5 mg/ml. After incubated with 20 μl of MTT for 4 h at 37 °C, the medium was aspirated and dimethyl sulfoxide (DMSO) was added to dissolve formazan. The absorbance was measured at a wavelength of 570 nm using an

automated Microplate Reader. The experiment was performed in triplicate.

### Colony formation assay

After the treatments of SW1116 cells, cells were trypsinized to single-cell suspensions of 1000 cells and plated in 6-well plates. The plates were incubated at 37 °C in 5%  $\rm CO_2$ until sufficiently large clones were formed. The colonies were fixed with4% paraformaldehyde and stained with 0.5% crystal violet for 30 min.

### **Transfection assay**

SW1116 cells were seeded into 6-well plates the day before transfection. The transfection was performed using Lipofectamine 3000 (Invitrogen) according to the manufacturer's instructions.

### **Target prediction**

Target miRNAs for *PAK4* and *BCAR3* were predicted using the TargetScan database (http://www.targetscan.org) and DIANA database (http://diana.imis.athena-innovation.gr).

### RNA extraction and real-time PCR

Total RNA from cells was extracted using Transzol reagent (Transgen) and then was converted into cDNA using the Transcript miRNA First-Strand cDNA Synthesis SuperMix (Transgen). In the 7500 Real-Time PCR System (ABI), quantitative reverse transcription was carried out in a 20 ul reaction system. qRT-PCR primers for PAK4 were F: 5'-TCCCCCTGAGCCATTGTG -3', R: 5'-TGACCTGTCTCCCCATCCA-3'.qRT-PCR primers for BCAR3 were F: 5'-GCGGTGGAACTGAAG GATTC-3', R: 5' -TGGCAGTTTGGGTGTACTGG-3'. GAPDH was used as internal control: 5'-GGACCTGAC CTGCCGTCTAG-3' and 5'-GTAGCCCAGGATGCC CTTGA-3'. qRT-PCR primers for miR-199a/b-3p was F: 5'-GTCACAGTAGTCTGCACAT-3'. U6 was used as internal control: 5'-CTCGCTTCGGCAGCACA-3' and 5'-AACGCTTCACGAATTTGCGT-3'. The  $2^{-\Delta\Delta Ct}$ method was used to analyze the expression levels of gene and miRNA.

### **Dual luciferase reporter assay**

The total cDNA from the SW1116 cells was used to amplify the 3'-UTR of *PAK4* and *BCAR3* by PCR. Then, the potential miR-199-3pbinding sites were inserted into the pmirGLO (Promega) vector to construct luciferase reporter vector. HEK293T cells were transfected withmiR-199a/b-3p mimics or Mir-negative controls (Gene pharma). At the same time, Mut or WT reporter vector was co-transfected into HEK293T cells. Cells were harvested and lysed with extraction buffer48 h

after transfection. The results were assayed by Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. The nucleotide sequences for *PAK4* 3'UTR were: 50-GACCC TACTA CTGAA CTCCA GT-3', and the mutagenesis sequences for *PAK4* 30UTR-mut were: 5'-GACCC TACCGTGTAA CTCCA GT-3'. The nucleotide sequences for *BCAR3* 3'UTR were: 5'-GACCC TACTA CTGAA CTCCA GT-3', and the mutagenesis sequences for *BCAR3* 3'UTR-mut were: 5'-GACCC TACCGTGTAA CTCCA GT-3'.

### Scratch wound assay

Cells were plated in 6-well plates and incubated overnight. The scratches were made using a sterilized 10  $\mu$ l pipette tip. Then, culture medium was removed to eliminate dislodged cells. The scratch wound was observed at 0 and 24 h. All images were collected under the microscope. All experiments were repeated at least three times.

### Migration and invasion assays

Migration and invasion assays were performed in Transwell chambers (8 µm pore size, 24-well plate; Corning). 600 µl volume of 10% FBS-containing medium was added to the lower chamber and  $1\times10^4$  cells were diluted in a 200 µl volume of serum-free medium were added to the upper chamber. For invasion assay, the upper chambers were coated with diluted Matrigel (BD Biosciences). After incubation for 48 h at 37 °C with 5% CO $_2$ , cells on the upper surface of the membranes were removed using a cotton swab. The remaining cells were fixed with 4% formaldehyde and stained with 1% crystal violet. The cells were counted and photographed under the inverted microscope in three fields of the view.

### Western blotting

20 μg of total proteins were loaded onto 8–10% polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were subsequently blocked with 5% non-fat milk in TBST for 1 h at room temperature. The membranes were incubated with primary antibodies including *PAK4* (Cell Signaling Technology, dilution 1:1000) and *BCAR3* (Bethyl Laboratories, dilution 1:1000) at 4 °C overnight. GAPDH (Santa Cruz Biotechnology, dilution 1:1000) was used as the loading control. After washing 3 times, the membranes were incubated with anti-rabbit or anti-mouse IgG HRP-linked (Cell Signaling Technology, dilution 1:3000) secondary antibody at room temperature for 1 h and visualized by enhanced chemiluminescence detection kit (Thermo Fisher).

### Statistical analysis

All statistical analysis was performed using SPSS 22.0 software. Data were presented as the mean  $\pm$  SD and differences between groups were analyzed using Student's t test. P<0.05 was considered statistically significant.

### Results

### Silence of *PAK4* inhibited proliferation and colony formation in CRC


To investigate the role of *PAK4* in CRC cells, we silenced *PAK4* expression by transfecting *PAK4* siRNA expression vectors in SW1116 cells. The results from western blot showed that *PAK4* was significantly decreased in the cells transfected with *PAK4* siRNA vectors (Fig. 1A). MTT and colony formation assay indicated that the knockdown of *PAK4* significantly inhibited the proliferation and decreased the number of colonies in SW1116 cells (Fig. 1B–D). However, scratch wound and transwell assays showed that the knockdown of *PAK4* had no significant effect on migration and invasion of SW1116 cells (Fig. 1E–H). These results indicated the role of *PAK4* in colorectal cell proliferation and colony formation.

### Silence of BCAR3 inhibited cell migration and invasion in CRC


To investigate the role of *BCAR3* in CRC cells, we silenced *BCAR3* expression by transfecting *BCAR3* siRNA expression vectors in SW1116 cells. The results from western blot showed that *BCAR3* was significantly decreased in the cells transfected with *BCAR3* siRNA vectors (Fig. 2A). MTT and colony formation assay indicated that the knockdown of *BCAR3*had no significant effect on proliferation and colony formation in SW1116 cells (Fig. 2B–D). Scratch wound and transwell assays showed that the knockdown of *BCAR3* significantly inhibited cell migration and invasion of SW1116 cells (Fig. 2E–H). These results indicated the role of *BCAR3* in colorectal cell migration and invasion.

### miR-199a/b-3p was the target miRNA of PAK4 and BCAR3


Given that *PAK4* and *BCAR3* had different roles on CRC cells and the diversity of miRNA targets, we screened out potential target miRNAs of these two genes by bio-informatics analysis. According to the results from TargetScan and DIANA database, we chose miR-199a/b-3p as the target miRNA (Fig. 3A). There are two potential target sites for miR-199a/b-3p at position 128–153 and 583–606 of *PAK4* mRNA 3'UTR (Fig. 3B). There are four potential target sites for miR-199a/b-3p at position 224–239, 262–276,381–401, and 1188–1208 of *BCAR3* mRNA 3'UTR (Fig. 3C). Luciferase reporter assay was conducted to examine the hypothesis that miR-199a/b-3p targeted



**Fig. 1** Silence of PAK4 inhibited proliferation and colony formation in CRC. **A** Western blot was used to measure the protein levels of the PAK4 and GAPDH protein in SW1116 cells transfected with PAK4 siRNA expression plasmid. GAPDH was used as the loading control. **B** MTT assay was performed on SW1116 cells transfected with PAK4 siRNA expression plasmid; \*\*p < 0.01. **C**, **D** Colony formation assay was performed on SW1116 cells transfected with PAK4 siRNA expression plasmid; \*\*p < 0.01. **E**, **F** Cell migration was analyzed using scratch wound assay. (bar, 200  $\mu$ m). **G**, **H** Cell invasion was analyzed using transwell assay. (bar, 100  $\mu$ m)



**Fig. 2** Silence of BCAR3inhibited cell migration and invasion in CRC. **A** Western blot was used to measure the protein levels of the BCAR3 and GAPDH protein in SW1116 cells transfected with BCAR3 siRNA expression plasmid. GAPDH was used as the loading control. **B** MTT assay was performed on SW1116 cells transfected with BCAR3 siRNA expression plasmid. **C**, **D** Colony formation assay was performed on SW1116 cells transfected with BCAR3 siRNA expression plasmid. **E**, **F** Cell migration was analyzed using scratch wound assay (bar, 200  $\mu$ m); \*\*p<0.01. (G, H) Cell invasion was analyzed using transwell assay (bar, 100  $\mu$ m); \*\*p<0.01



**Fig. 3** miR-199a/b-3p was the target of PAK4 and BCAR3. **A** TargetScan and DIANA database were used to predict the target miRNAs of PAK4 and BCAR3. **B** Sequences of predicted miR-199a/b-3p binding sites within PAK4 3'-UTR in DIANA database. **C** Sequences of predicted miR-199a/b-3p binding sites within BCAR3 3'-UTR in DIANA database. **D**, **E** Effect of miR-199a/b-3p on luciferase intensity controlled by the wild type (WT) or mutant (MUT) 3'UTR of PAK4/BCAR3 was determined using the luciferase assay; \*\*p < 0.01. **F**, **G** mRNA levels of PAK4/BCAR3 were detected using quantitative RT-PCR in SW1116 cells transfected with miR-199a/b-3p mimics; \*\*p < 0.01. **H** Protein levels of PAK4 and BCAR3 were detected using western blot in SW1116 cells transfected with miR-199a/b-3p mimics

the 3'-UTR of *PAK4* and *BCAR3*. The results indicated that miR-199a/b-3p significantly decreased the luciferase activity of the reporter with wild type 3'-UTR of *PAK4* and *BCAR3* (Fig. 3D, E). qRT-PCR and western blot analyses verified that miR-199a/b-3p decreased *PAK4* and *BCAR3* expression at mRNA and protein levels in SW1116 cells (Fig. 3F–H). Results showed that miR-199a/b-3p could directly target the 3'-UTR of *PAK4* and *BCAR3*.


### miR-199a/b-3p inhibited cell proliferation and colony formation in CRC

To further explore the role of miR-199a/b-3p in colorectal cells, we transfected the miR-199a/b-3p mimics

or negative controls into SW1116 cells. qRT-PCR was used to detect the relative expression of miR-199a/b-3p. The level of miR-199a/b-3p was significantly increased in mimics transfected cells (Fig. 4A). MTT and colony formation assays indicated that miR-199a/b-3p mimics inhibited the proliferation and decreased the number of colonies in SW1116 cells (Fig. 4B–D).

### miR-199a/b-3p inhibited cell migration and invasion in CRC

We then determined the effect of miR-199a/b-3p on migration and invasion. Scratch wound assay results showed that themiR-199a/b-3p mimics significantly inhibited the migratory ability of SW1116 cells (Fig. 5A,



**Fig. 4** miR-199a/b-3p inhibited cell proliferation and colony formation in CRC. **A** Levels of miR-199a/b-3p were detected using quantitative RT-PCR in SW1116 cells transfected with miR-199a/b-3p mimics; \*\*p < 0.01. **B** MTT assay was performed on SW1116 cells transfected with miR-199a/b-3p mimics; \*\*p < 0.01. **C**, **D** Colony formation assay was performed on SW1116 cells transfected with miR-199a/b-3p mimics; \*\*p < 0.01

B). Transwell assay results showed that miR-199a/b-3p mimics also significantly inhibited the invasive ability of SW1116 cells (Fig. 5C, D). These results indicated that miR-199a/b-3p could suppress cell migration and invasion in CRC cells.

## The effects of miR-199a/b-3p on cell proliferation, migration, and invasion could be partially reversed by *PAK4* and *BCAR3* overexpression


Since the inhibitory effects of miR-199a/b-3p included the effects of silencing *PAK4* and *BCAR3*, we examined that whether the function could be reversed by overexpressing *PAK4* or *BCAR3*. We transfected negative controls, miR-199a/b-3p mimics, miR-199a/b-3p+*BCAR3*, or miR-199a/b-3p+*PAK4* in SW1116 cells. MTT and colony formation assays showed that the restoration of *PAK4* expression reversed the effect of miR-199a/b-3p on cell proliferation and colony formation (Fig. 6A–C). The results from scratch wound and transwell assays showed that ectopic *BCAR3* expression reversed the inhibitory effect of miR-199a/b-3p on cell migration and invasion (Fig. 6D–G). The above results indicated that miR-199a/b-3p inhibited viability and mobility of CRC cells by targeting *PAK4* and *BCAR3*, respectively.

### **Discussion**

CRC is a complex disease and one of the main causes of death from cancer worldwide [19, 20]. The morbidity of CRC is increasing every year. Meanwhile the global incidence of CRC is expected to increase to 2.5 million by 2035 [21]. Although the life expectancy for CRC patients has increased as a result of advances in screening and treatment, the prognosis of these patients remains poor [22]. Therefore, it is of great significance to understand the underlying mechanism of its occurrence and development and to find out the approaches to overcome the poor prognosis.

*PAK4* has been reported to be involved in the regulation of cell cycle regulatory proteins p21, p16, and CDK6 [23]. Studies showed that the down-regulation of *PAK4* had inhibitory effects on CRC cells [10, 11]. Consistent with these previous reports, our study demonstrated that the knockdown of *PAK4* significantly inhibited the proliferation and colony formation of SW1116 cells. However, there was no significant effect on migration and invasion.

Recently, reports have shown that the overexpression of *BCAR3* could regulate cytoskeletal rearrangement and improved the cell migration and invasion in endometriosis [13, 14]. However, there no relevant studies conducted on the role of *BCAR3* in CRC. Therefore, we knocked




**Fig. 5** miR-199a/b-3p inhibited cell migration and invasion in CRC. **A, B** SW1116 cells were transfected with miR-199a/b-3p mimics. Cell migration was analyzed using scratch wound assay. (bar, 200  $\mu$ m). **C, D** SW1116 cells were transfected with miR-199a/b-3p mimics. Cell invasion was analyzed using transwell assay. (bar, 100  $\mu$ m)

down the expression of *BCAR3* to explore the role of *BCAR3* in CRC. Results showed that the knockdown of *BCAR3* significantly inhibited cell migration and invasion of SW1116 cells, but there was no significant effect on proliferation and colony formation.

MiRNAs are endogenous non-coding small RNAs, which play important roles in plants and animals [24]. They inhibit the gene translation or degrading the target mRNA by binding to the 3'-untranslated region

(3'-UTR) of target genes [25]. A single miRNA can target numerous mRNA and regulate the expression of multiple genes, which involved in cancer progression in multiple ways. Much more studies have shown that miRNAs play essential roles in promoting or inhibiting the proliferation, invasion, apoptosis and drug resistance of tumor cells by regulating some key genes [26–28]. Some studies revealed that miRNAs are involved in progression of CRC [29, 30].



**Fig. 6** Effects of miR-199a/b-3p could be partially reversed by PAK4 and BCAR3 overexpression. **A** MTT assay was performed on SW1116 cells transfected with miR-199a/b-3p mimics and/or PAK4/BCAR3 overexpression plasmid; \*\*p < 0.01. **B, C** Colony formation assay was performed on SW1116 cells transfected with miR-199a/b-3p mimics and/or PAK4/BCAR3 overexpression plasmid; \*\*p < 0.01. **D, F** Cell migration was analyzed using scratch wound assay. (bar, 200  $\mu$ m);\*\*p < 0.01. **E, G** Cell invasion was analyzed using transwell assay. (bar, 100  $\mu$ m);\*\*p < 0.01

Considering the different roles of *PAK4* and *BCAR3* on CRC cells and the multiple targets of miRNA, we decided to predict the potential target miRNAs of *PAK4* and *BCAR3*. From the results in TargetScan and DIANA

database, we surprisingly found miR-199a/b-3p could be the target miRNA of both genes. Our luciferase reporter assay results showed that *PAK4* and *BCAR3* were potential targets of miR-199a/b-3p in SW1116 cells. Moreover,

qRT-PCR and western blot analyses verified that miR-199a/b-3p decreased *PAK4* and *BCAR3* expression at mRNA and protein levels in SW1116 cells, which meant that miR-199a/b-3p could directly target the 3'-UTR of *PAK4* and *BCAR3*.

As for miR-199a/b-3p, there are several studies of its suppressive role in tumor progression. MiR-199a/b-3p could suppress hepatocellular carcinoma through inhibiting *PAK4/Raf/MEK/ERK* pathway [31]. In this study, our results indicated that miR-199a/b-3p significantly inhibited the proliferation, colony formation, migration, and invasion of SW1116 cells.

We then performed rescue experiments to explore whether *PAK4* and *BCAR3* were downstream functional regulators involved in miR-199a/b-3p regulation in SW1116 cells. Overexpression of *PAK4* significantly alleviated the effects of miR-199a/b-3p in SW1116 cells on cell proliferation and colony formation. Meanwhile, the overexpression of *BCAR3* significantly reversed the effects of miR-199a/b-3p in SW1116 cells on cell migration and invasion. The above results indicated that miR-199a/b-3p inhibited the proliferation, colony formation of SW116 cells through targeting *PAK4*. Meanwhile, the inhibitory effects on migration and invasion were regulated by targeting *BCAR3*.

In summary, our research demonstrated that miR-199a/b-3p inhibited viability and mobility of CRC cells by regulating *PAK4* and *BCAR3*, respectively. This study proposed a new miRNA for filtrating multi-targeted neoplastic suppressant to improve the prognosis of CRC in patients.

### **Abbreviations**

CRC: Colorectal cancer; *PAK4*: P21 activated kinase 4; *BCAR3*: The breast cancer anti-estrogen resistance 3; SW116: Human colorectal cancer cells; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; DMSO: Dimethyl sulfoxide; PBS: Phosphate-buffered saline; PVDF: Polyvinylidene fluoride.

### Acknowledgements

We gratitude all the funders and experimenters. The manuscript does not include any individual data.

### **Author contributions**

Conceptualization: N-Y. Data curation: XM, NL, X-NL, XL, and YF. Formal analysis: YF and N-YJ. Funding acquisition: N-YJ. Investigation: N-YJ. Methodology and visualization: XL. Resources: JH. Software: XM. Writing—original draft: JH, YF, X-NL, and N-YJ. Writing—review and editing: JH, YF, YY, and N-YJ.

### Funding

The present study was funded by the China Postdoctoral Science Foundation (2015M581404), the Research Foundation of Jilin Provincial Science & Technology Development (20170414038GH; 20180414037GH; 20200201359JC; 2021Y024), and the Research Foundation of Health and Family Planning Commission of Jilin Province (2017Q003).

### Availability of data and materials

All data supporting the conclusions of this article are included within the

### **Declarations**

### Ethics approval and consent to participate

There was no ethics approval for the use of the cell lines in current pilot.

### Consent for publication

Not applicable. (The manuscript has never been published before, and the author agrees to publish it in your journal. The copyright is transferred to your journal If and when the article is accepted for publication).

#### Competing interests

The authors declare that they have no competing interests.

#### **Author details**

<sup>1</sup>Medical College, Yanbian University, Yanji 133002, China. <sup>2</sup>Tumor Biotherapy Center, Jilin Province People's Hospital, Changchun, China. <sup>3</sup>General Surgery of The First Clinical Hospital of Jilin Academy of Chinese Medicine Sciences, Changchun, China. <sup>4</sup>Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun, China.

Received: 3 February 2022 Accepted: 1 July 2022 Published online: 16 July 2022

#### References

- Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
- 3. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–80.
- Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–7.
- Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem. 2003;72:743–81.
- Liu D, Jian X, Xu P, Zhu R, Wang Y. Linc01234 promotes cell proliferation and metastasis in oral squamous cell carcinoma via miR-433/PAK4 axis. BMC Cancer. 2020;20(1):107.
- Zhang X, Fang J, Chen S, Wang W, Meng S, Liu B. Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4. Cancer Med. 2019;8(12):5716–34.
- Mao K, Lei D, Zhang H, You C. MicroRNA-485 inhibits malignant biological behaviour of glioblastoma cells by directly targeting PAK4. Int J Oncol. 2017;51(5):1521–32.
- Phatak P, Burrows WM, Chesnick IE, Tulapurkar ME, Rao JN, Turner DJ, Hamburger AW, Wang JY, Donahue JM. MiR-199a-3p decreases esophageal cancer cell proliferation by targeting p21 activated kinase 4. Oncotarget. 2018;9(47):28391–407.
- Sheng N, Tan G, You W, Chen H, Gong J, Chen D, Zhang H, Wang Z. MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway. Cancer Med. 2017;6(6):1331–40.
- Wang M, Gao Q, Chen Y, Li Z, Yue L, Cao Y. PAK4, a target of miR-9-5p, promotes cell proliferation and inhibits apoptosis in colorectal cancer. Cell Mol Biol Lett. 2019;24:58.
- Vervoort VS, Roselli S, Oshima RG, Pasquale EB. Splice variants and expression patterns of SHEP1, BCAR3 and NSP1, a gene family involved in integrin and receptor tyrosine kinase signaling. Gene. 2007;391(1–2):161–70.
- 13. Dorssers LC, van Agthoven T, Brinkman A, Veldscholte J, Smid M, Dechering KJ. Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. Breast Cancer Res. 2005;7(1):R82-92.

- Meng X, Liu J, Wang H, Chen P, Wang D. MicroRNA-126-5p downregulates BCAR3 expression to promote cell migration and invasion in endometriosis. Mol Cell Endocrinol. 2019;494: 110486.
- Burroughs AM, Ando Y. Identifying and characterizing functional 3' nucleotide addition in the miRNA pathway. Methods. 2019;152:23–30.
- Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–33.
- Fang Z, Yang H, Chen D, Shi X, Wang Q, Gong C, Xu X, Liu H, Lin M, Lin J, et al. YY1 promotes colorectal cancer proliferation through the miR-526b-3p/E2F1 axis. Am J Cancer Res. 2019;9(12):2679–92.
- Zhang Y, Zhang S, Yin J, Xu R. MiR-566 mediates cell migration and invasion in colon cancer cells by direct targeting of PSKH1. Cancer Cell Int. 2019;19:333.
- Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, The Global Burden of Cancer C, et al. The Global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27.
- Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H,
  Dicker DJ, Chimed-Orchir O, Dandona R, The Global Burden of Cancer C,
  et al. Global, regional, and national cancer incidence, mortality, years of
  life lost, years lived with disability, and disability-adjusted life-years for 32
  cancer groups, 1990 to 2015: a systematic analysis for the global burden
  of disease study. JAMA Oncol. 2017;3(4):524–48.
- Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.
- Soreide K, Berg M, Skudal BS, Nedreboe BS. Advances in the understanding and treatment of colorectal cancer. Discov Med. 2011;12(66):393–404.
- Nekrasova T, Minden A. PAK4 is required for regulation of the cell-cycle regulatory protein p21, and for control of cell-cycle progression. J Cell Biochem. 2011;112(7):1795–806.
- Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics. 2014;2014: 970607.
- Hu W, Coller J. What comes first: translational repression or mRNA degradation? The deepening mystery of microRNA function. Cell Res. 2012;22(9):1322–4.
- 26. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.
- 27. Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33(6):1126–33.
- Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–22.
- Wang J, Wang X, Liu F, Fu Y. microRNA-335 inhibits colorectal cancer HCT116 cells growth and epithelial-mesenchymal transition (EMT) process by targeting Twist1. Pharmazie. 2017;72(8):475–81.
- Yao GD, Zhang YF, Chen P, Ren XB. MicroRNA-544 promotes colorectal cancer progression by targeting forkhead box O1. Oncol Lett. 2018;15(1):991–7.
- Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19(2):232–43.

### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

### At BMC, research is always in progress.

**Learn more** biomedcentral.com/submissions

